What the FDA labels say about taking them together
Insulin aspart and octreotide
Insulin aspart's FDA label of June 21, 2023 names octreotide in its drug interactions section; octreotide's label does not name insulin aspart itself but warns about its class (insulin analogs). The insulin aspart label: “… inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics. Intervention: Dose reductions and increased frequency of glucose monitoring may be required …”
Check it at the source: the insulin aspart FDA label on DailyMed (effective June 21, 2023, Novo Nordisk); the octreotide FDA label on DailyMed (effective July 22, 2026, Novartis Pharmaceuticals Corporation).
What does the insulin aspart label say about octreotide?
Insulin aspart label, drug interactionsDrugs That May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics. Intervention: Dose reductions and increased frequency of glucose monitoring may be required when FIASP is co-administered with these drugs.
Source: FDA drug label (Insulin Aspart, BLA020986), Novo Nordisk Pharma, Inc., effective February 28, 2023 (SPL set bee5b358-c863-420b-be73-ced2e920c499), via openFDA
Source: FDA drug label (Fiasp), Novo Nordisk, effective June 21, 2023 (SPL set 834e7efc-393f-4c55-9125-628562a8a5cf), via openFDA; the full label on DailyMed
What does the octreotide label say about insulin aspart?
Octreotide's label does not name insulin aspart itself; it warns about its class (insulin analogs):
Octreotide label, drug interactionsCyclosporine, insulin, oral hypoglycemic agents, beta-blockers, and bromocriptine. ( 7 ) Lutetium Lu 177
Octreotide label, drug interactionsOctreotide inhibits the secretion of insulin and glucagon.
Source: FDA drug label (Sandostatin), Novartis Pharmaceuticals Corporation, effective July 22, 2026 (SPL set 4e2c9856-1836-49f0-9472-4dbeeb408f39), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Insulin aspart | Octreotide | |
|---|---|---|
| Labeled for | Type 2 diabetes, Type 1 diabetes | Diarrhea |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $6.95 per mL 100 unit/mL vial | $2.53 per mL 100 mcg/mL vial |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once